Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Mental health conditions

FDA approves first drug for tardive dyskinesia

The US Food and Drug Administration (FDA), which is responsible for evaluating the safety and efficacy of medicines in the United States, has given the green light to valbenazine (Ingrezza), the first drug to be approved for treating adults with tardive dyskinesia.

Tardive dyskinesia is a neurological disorder characterised by repetitive, involuntary movements of the jaw and lips, such as grimacing and lip-smacking. It is a side effect sometimes seen in patients who have been treated with antipsychotic medications for long periods, such as those for schizophrenia and bipolar disorder, although it is unknown why.

“Tardive dyskinesia can be disabling and can further stigmatise patients with mental illness,” says Mitchell Mathis, director of the Division of Psychiatry Products in the FDA’s Center for Drug Evaluation and Research. “This is an important advance for patients suffering with this condition.”

Valbenazine was approved following a clinical trial comprising 234 participants that compared the drug to a placebo. At six-week follow-up, those who had received valbenazine saw improvement in the severity of their abnormal involuntary movements compared with those who received a placebo.

Side effects of the drug include sleepiness and heart rhythm problems. Consequently, it should not be given to patients with congenital long QT syndrome.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2017.20202611

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • The US Food and Drug Administration (FDA)

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.